title: [Systemic lupus erythematosus with disease onset after age 65].
abstract: OBJECTIVE
  Systemic lupus erythematosus with disease-onset in the elderly has rarely been studied (only one report about 21 patients with disease onset at 65 and older). Is the management of this pathology modified in this population?
  
  
  METHODS
  Seventeen hospitalised cases of lupus patients with disease onset at 65 or older are retrospectively reported between 1988 and 2000. The results are compared with those of younger subjects.
  
  
  RESULTS
  The female to male ratio is 1.83. Mean age at disease onset is 71.9 +/- 3.5 years. Mean duration of follow-up is 3.5 +/- 2.4 years. Main initial symptoms are: deterioration of general status (41%), arthritis (35%), cutaneous manifestations (35%), thrombo-embolism (24%) and pleuritis (18%). Malar rash is uncommon (12%). Nephropathy is never a revealing symptom and is rarely serious during the disease's evolution. Like in neurologic manifestations, the etiology has to be discussed in relation to associated co-morbidities. Concerning haematologic features, lymphopenia is found in 82% of the cases with a questionable specificity. Antinuclear antibodies are constant, anti-dsDNA antibodies are found in 82% of the cases, antibodies to extractable nuclear antigens in 50%, and anticoagulant circulating activity in 59%. Prognosis is difficult to assess in such a limited series but 5-years survival probability is 83%. Glucocorticoid lead to 50% of major complications.
  
  
  CONCLUSIONS
  This study focuses on the particular initial manifestations of systemic lupus erythematosus in the elderly (deterioration of general status, thrombosis, unusual cutaneous symptoms), and on the specificity of differential diagnosis and treatment.
authors.affiliation: Hôpital gériatrique Antoine-Charial, centre hospitalier universitaire de Lyon, 40, avenue de la Table-de-Pierre, 69340 Francheville, France. sylvain.gaujard@chu-lyon.fr
authors.forename: S
authors.initials: S
authors.lastname: Gaujard
authors.forename: C
authors.initials: C
authors.lastname: Broussolle
authors.forename: P
authors.initials: P
authors.lastname: Cathebras
authors.forename: J-L
authors.initials: JL
authors.lastname: Dupond
authors.forename: C
authors.initials: C
authors.lastname: Massot
authors.forename: J
authors.initials: J
authors.lastname: Ninet
authors.forename: H
authors.initials: H
authors.lastname: Perrot
authors.forename: D Vital
authors.initials: DV
authors.lastname: Durand
authors.forename: H
authors.initials: H
authors.lastname: Rousset
mesh_terms: D017677:Age Distribution; D017668:Age of Onset; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000974:Antibodies, Antinuclear / Q000097:blood; D034961:Antigens, Nuclear / Q000276:immunology; D015897:Comorbidity; D003937:Diagnosis, Differential; D005260:Female; D005602:France / Q000453:epidemiology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D015994:Incidence; D008180:Lupus Erythematosus, Systemic / Q000175:diagnosis* / Q000188:drug therapy* / Q000453:epidemiology / Q000209:etiology; D008297:Male; D011379:Prognosis; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D012307:Risk Factors; D017678:Sex Distribution; D013256:Steroids; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; D000974:Antibodies, Antinuclear; D034961:Antigens, Nuclear; D007166:Immunosuppressive Agents; D013256:Steroids